- Sanara Medtech Inc SMTI.OQ SMTI.O is expected to show a rise in quarterly revenue when it reports results on August 13 for the period ending June 30 2025 
- The Fort Worth Texas-based company is expected to report a 24.8% increase in revenue to $25.15 million from $20.16 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data. 
- LSEG's mean analyst estimate for Sanara Medtech Inc is for a loss of 44 cents per share. 
- The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." 
- The mean earnings estimate of analysts was unchanged in the last three months.  
- Wall Street's median 12-month price target for Sanara Medtech Inc is $49.00, about 49.4% above its last closing price of $24.80 
This summary was machine generated August 11 at 12:35 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)